Chipiron

Chipiron

Paris, France· Est.

Chipiron is a pioneering medtech startup building a disruptive, ultra-low-field (<10 mT) full-body MRI scanner designed to be lightweight, affordable, and operable without shielded rooms or specialized technicians. The company has secured significant non-dilutive grants and equity financing, including a $17M Series A and a major EIC Accelerator award, validating its ambitious vision. With a roadmap targeting first in-vivo images in 2025 and FDA clearance in 2028, Chipiron aims to revolutionize medical imaging by making MRI screening and image-guided therapies accessible on a global scale.

Private Company

Total funding raised: $20.3M

AI Company Overview

Chipiron is a pioneering medtech startup building a disruptive, ultra-low-field (<10 mT) full-body MRI scanner designed to be lightweight, affordable, and operable without shielded rooms or specialized technicians. The company has secured significant non-dilutive grants and equity financing, including a $17M Series A and a major EIC Accelerator award, validating its ambitious vision. With a roadmap targeting first in-vivo images in 2025 and FDA clearance in 2028, Chipiron aims to revolutionize medical imaging by making MRI screening and image-guided therapies accessible on a global scale.

OncologyDiagnostic Imaging

Technology Platform

An integrated ultra-low-field (<10 mT) MRI platform combining a patented quantum SQUID detection system, AI-powered noise cancellation, a lightweight cryostat, and advanced AI reconstruction to enable lightweight, affordable, full-body MRI without shielded rooms.

Funding History

3
Total raised:$20.3M
Series A$15M
Seed$2.8M
Seed$2.5M

Opportunities

The primary opportunity is to unlock the massively underserved global MRI market, particularly in low-resource settings and for point-of-care applications in developed countries.
By reducing cost and complexity 100-fold, Chipiron could enable widespread cancer screening and transform diagnostic workflows.

Risk Factors

Key risks include technical execution challenges in integrating quantum sensors and AI, regulatory hurdles in proving equivalence for a novel device, and market adoption barriers in the conservative healthcare sector.
Manufacturing scale-up also presents a significant challenge.

Competitive Landscape

Main competitors include incumbent high-field MRI giants (Siemens, GE, Philips) and portable MRI startups like Hyperfine (brain-only) and Synaptive. Chipiron differentiates by targeting a full-body, ultra-portable system using quantum SQUID detection and aiming for radical affordability without shielded rooms.